Regeneron/REGN
$982.29
1.47%-
1D1W1MYTD1YMAX
About Regeneron
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Ticker
REGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Leonard Schleifer
Employees
13,450
Headquarters
Tarrytown, United States
Website
www.regeneron.com
Regeneron Metrics
BasicAdvanced
$108B
Market cap
28.89
P/E ratio
$33.86
EPS
0.13
Beta
-
Dividend rate
Price and volume
Market cap
$108B
Beta
0.12579
52-week high
$998.33
52-week low
$684.81
Average daily volume
454K
Financial strength
Current ratio
5.27
Quick ratio
4.512
Long term debt to equity
10.016
Total debt to equity
10.016
Enterprise value to free cash flow
28.691
Management effectiveness
Return on assets (TTM)
11.98%
Return on equity (TTM)
15.28%
Return on investment (TTM)
13.36%
Valuation
Price to earnings (TTM)
28.889
Price to revenue (TTM)
8.228
Price to book
3.994
Price to tangible book (TTM)
4.156
Price to free cash flow (TTM)
27.427
Growth
Revenue change (TTM)
5.9%
Earnings per share change (TTM)
-8%
3-year revenue growth
15.57%
3-year earnings per share growth
4.44%
What the Analysts think about Regeneron
Analyst Ratings
Majority rating from 29 analysts.
Price Targets
Average projection from 24 analysts.
High $1,185.00
Low $720.00
$982.29
Current price
$1,057.56
Average price target
Regeneron Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.1B
-8.42%
Net income
$722M
-37.74%
Profit margin
22.95%
-32.02%
Regeneron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$10.24
$11.59
$11.86
$9.55
-
Expected
$9.84
$10.72
$10.73
$10.09
$10.63
Surprise
4.03%
8.13%
10.53%
-5.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $108B as of May 20, 2024.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 29.01 as of May 20, 2024.
Does Regeneron stock pay dividends?
No, Regeneron (REGN) stock does not pay dividends to its shareholders as of May 20, 2024.
When is the next Regeneron dividend payment date?
Regeneron (REGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Regeneron stock price target?
The target price for Regeneron (REGN) stock is $1059.86, which is 7.9% above the current price of $982.29. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Regeneron stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.